Company

CytomX Therapeutics

As of the edition of 20 October 2026, CytomX Therapeutics runs 7 drugs; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Active2
Stopped4
Status not established1
Total7

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
ALCAM CD166 antigenRoute A
CD274 Programmed cell death 1 ligand 1Route A
EGFR Epidermal growth factor receptorRoute A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Cancer: 5 trials led
  • Skin and connective tissue: 3 trials led
  • Blood and lymph: 2 trials led